CJC-1295 DAC
- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Most growth hormone–releasing peptides are out of your system in under an hour. CJC-1295 DAC stays active for up to eight days per injection. That single difference is why it became one of the most-discussed GH research peptides in the world — and why the regular CJC-1295 has stopped being interesting to most researchers who can choose.
What Is CJC-1295 DAC?
CJC-1295 DAC is a synthetic 29-amino-acid GHRH analog — basically a re-engineered version of the natural growth hormone–releasing hormone your hypothalamus produces. The "DAC" stands for Drug Affinity Complex: a small molecular tag that lets the peptide grab onto serum albumin in the blood and ride along with it instead of getting cleared in minutes.
That single design choice changes everything. Native GHRH lives for about 7 minutes. CJC-1295 without DAC lasts about 30 minutes. Add the DAC, and the half-life jumps to roughly 6 to 8 days. In published human research, a single injection raised plasma GH levels 2- to 10-fold for 6+ days and IGF-1 by 0.5- to 3-fold for up to 11 days. Multi-dose protocols kept IGF-1 elevated for 28 days. That's a different research tool entirely.
The ConjuChem Engineering That Made It Possible
CJC-1295 was developed by ConjuChem, a Canadian biotech, in the mid-2000s. The team didn't invent a new peptide — they took the active 29-amino-acid fragment of GHRH (also called GRF 1-29, the same core sequence as Sermorelin) and made four targeted amino acid substitutions to resist enzymatic breakdown. Then they bolted on the DAC tag, a lysine-linked maleimidopropionic acid derivative that covalently bonds to albumin once injected.
The breakthrough wasn't the GHRH activity. That was already known. The breakthrough was making it last — turning a peptide that needed multiple daily injections into one that could be dosed weekly. That's the engineering that put CJC-1295 DAC on the map and kept it there.
What Serious Buyers Should Know
The long half-life is the selling point. It's also the trade-off. Native GHRH releases growth hormone in pulses — that's how the body actually uses it. CJC-1295 DAC produces something closer to a constant elevated baseline, sometimes called a "GH bleed." Some researchers want exactly that for endocrinology studies. Others prefer non-DAC versions or shorter analogs like Tesamorelin specifically because pulsatile release is more physiologically realistic. There's no consensus on which approach wins. There's just two different research tools for two different questions.
Regulatory note: CJC-1295 (including the DAC version) was placed on the FDA's Category 2 bulks list in 2023, then removed from Category 2 in September 2024 after the original nominations were withdrawn. A PCAC review was scheduled to determine whether CJC-1295 and its DAC variants would be added to the Category 1 bulks list. As of May 2026, formal Category 1 listing has not been finalized — the compound sits in regulatory transition. WADA prohibits it for athletes in tested sports.
Why Generic Peptides for CJC-1295 DAC?
Here's what's specific to CJC-1295 DAC: the DAC modification is what makes the compound work. Without it, you have plain CJC-1295 (or Modified GRF 1-29), which has a 30-minute half-life and an entirely different research profile. Cheap synthesis routes routinely sell either an incomplete DAC linkage or simply the non-DAC version under the DAC label. Most buyers can't distinguish them without HPLC analysis. If you're studying long-acting GHRH activity and the DAC isn't intact, your data won't replicate published research.
Generic Peptides supplies research-grade CJC-1295 DAC for sale at 99% purity, manufactured in the USA. Domestic synthesis with full DAC conjugation verified — not just a label that says so.
Order CJC-1295 DAC for sale in the USA — 99% purity, full DAC conjugation, 8-day half-life intact.
CJC-1295 DAC FAQ
Is it legal to buy CJC-1295 DAC in the US for research?
Yes — CJC-1295 DAC is legally available in the United States as a research compound. It was removed from the FDA's Category 2 list in September 2024, and final compounding status is pending PCAC review. It's not FDA-approved for human use, and WADA prohibits it for tested athletes.
What's the actual difference between CJC-1295 DAC and CJC-1295 (no DAC)?
The peptide sequence is essentially the same — what differs is the DAC tag attached to it. CJC-1295 without DAC has a half-life around 30 minutes and produces pulsatile GH release. CJC-1295 DAC binds to albumin and lasts 6–8 days, producing sustained elevation rather than pulses. They're studied for completely different research questions.
I've seen this sold for half the price elsewhere — same compound?
Probably not. The DAC modification is the expensive, technically demanding part of the synthesis. Cheap suppliers routinely sell non-DAC CJC-1295 mislabeled as DAC, or use incomplete linkage chemistry that breaks down quickly. The price gap usually reflects what's actually in the vial.
Is CJC-1295 DAC the same as Modified GRF 1-29 or Sermorelin?
Related but distinct. Sermorelin is the unmodified GRF 1-29 sequence. Modified GRF 1-29 has the four amino acid substitutions but no DAC. CJC-1295 DAC has both the substitutions and the DAC tag. All three target the same GHRH receptor, but their pharmacokinetics are completely different.
Wait — does the FDA actually allow this now?
Sort of. CJC-1295 (free base, acetate) and CJC-1295 with DAC (free base, DAC acetate, DAC trifluoroacetate) were removed from Category 2 in September 2024 after nomination withdrawals. They are not currently restricted, but final inclusion on the Category 1 bulks list requires PCAC approval which remains pending as of May 2026. In the meantime, sales as a research compound continue legally.
Sources
Teichman SL et al. — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006. Documents the 6-day GH elevation and DAC pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/16352683/
Alba M et al. — "Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology - Endocrinology and Metabolism, 2006. Supports the DAC mechanism and albumin-binding pharmacokinetics. https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006
FDA — "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A," updated 2024–2026. Documents CJC-1295 and CJC-1295 DAC removal from Category 2 effective September 27, 2024. https://www.fda.gov/media/94155/download
Lexology — "FDA removes certain peptide bulk drug substances from Category 2." Industry analysis of the September 2024 reclassification including specific CJC-1295 DAC variants. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
8-day half-life only matters if the DAC is actually attached. 99% purity, USA-made, conjugation verified.
CJC-1295 DAC Dosage Guide
CJC-1295 DAC is a long-acting synthetic GHRH analog modified with a Drug Affinity Complex that binds reversibly to serum albumin, extending the half-life to 6–8 days and enabling weekly dosing. This guide is aimed at users targeting body recomposition, improved sleep quality, recovery, and anti-aging effects through sustained GH/IGF-1 elevation. Dosing below comes from the Teichman et al. Phase 1/2 clinical trials (published in JCEM, 30–60 mcg/kg single and weekly doses), the discontinued Conjuchem development program, and community protocols that have standardized around the 1–2 mg weekly range.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 500–1000 mcg | Once weekly, SC, evening | Start at 1 mg; wait 4 weeks before adjusting |
| Standard | 2000 mcg (2 mg) | Once weekly, SC, evening | Most common community protocol and research reference dose |
| Intermediate | 1000 mcg | Twice weekly (Mon/Thu), SC | Split dosing for steadier GH exposure |
| Aggressive | 2000–3000 mcg | Split twice weekly, SC | Upper end of community protocols; minimal additional benefit above 2 mg/week |
| Clinical research | 30–60 mcg/kg | Weekly or biweekly, SC | Teichman 2006 Phase 2 range (~2.1–4.2 mg for 70 kg subject) |
Doses also shift depending on the specific goal. The same peptide used for sleep and general recovery versus muscle gain cycles can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Anti-aging / general GH support | 1000 mcg | Once weekly, SC | 8–12 weeks on / 4–6 weeks off |
| Fat loss / body recomposition | 1000–2000 mcg | Once weekly, SC | 12 weeks on / 4 weeks off |
| Muscle gain / athletic recovery | 2000–3000 mcg | Split twice weekly, SC | 12–16 weeks on / 4–6 weeks off |
| Sleep quality / deep sleep support | 1000 mcg | Once weekly, SC, evening | 8–12 weeks |
| Tissue repair / injury recovery | 2000 mcg | Once weekly, SC | 8 weeks |
| Stacked with Ipamorelin | 1000 mcg CJC + 200–300 mcg Ipamorelin daily | CJC once weekly + Ipamorelin pre-bed daily | 8–12 weeks |
Dose in the evening at least 2 hours after your last meal — elevated insulin blunts GH release and negates much of the peptide's effect, regardless of how much you inject. Avoid going above 2 mg per week; clinical data shows diminishing returns, and higher doses primarily increase water retention, tingling, and injection-site flushing rather than outcomes. Absolute contraindications include active cancer diagnosis (elevated IGF-1 is mitogenic), diabetic retinopathy, and pregnancy — anyone with a history of cancer or pre-cancerous conditions should consult an oncologist before any dose.
CJC-1295 DAC Storage Guide: How to Keep Your Research Peptide Stable and Effective
CJC-1295 DAC ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its modified GHRH structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a frost-free freezer with temperature swings, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Based on 1 reviews
5.0
Stacking with Ipamorelin for the past 10 weeks. The synergy is real — better body composition, stronger workouts, and recovery that used to take two days now takes one. CJC DAC from here reconstitutes cleanly and the COA checks out. Reordering without hesitation.
The peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylyl cyclase and triggering the cAMP-PKA cascade that drives GH gene transcription and release. It works upstream — telling the pituitary to make and release more of its own GH rather than supplying GH directly. That distinction matters for any research focused on natural GH regulation.
Both are GHRH analogs, but Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has a half-life closer to 30 minutes. CJC-1295 DAC has the 6-8 day half-life through albumin binding. Tesamorelin produces pulsatile GH release; CJC-1295 DAC produces sustained elevation. Different tools for different research questions.
Ipamorelin works through a completely different receptor — the ghrelin/GHS receptor — rather than the GHRH receptor that CJC-1295 DAC targets. Researchers studying synergistic GH release combine the two because hitting both receptors simultaneously produces a stronger response than either alone. The pairing is the most-cited GH peptide stack in the literature.
Published human studies show CJC-1295 DAC raises plasma IGF-1 by 0.5- to 3-fold for 9-11 days after a single injection. Multi-dose research kept IGF-1 elevated for up to 28 days. IGF-1 is the downstream effector of GH, so the IGF-1 response is what most researchers actually track when studying GH release dynamics.
The DAC modification is the technically demanding part — the lysine-linked maleimidopropionic acid moiety has to be conjugated correctly for albumin binding to work. Cheap synthesis produces incomplete linkage or skips it entirely, leaving you with non-DAC CJC-1295 sold under the DAC label. Without HPLC verification, the difference is invisible to buyers.
CJC-1295 was developed by ConjuChem, a Canadian biotech firm, in the mid-2000s. The first published human pharmacokinetic studies appeared in 2006. The compound was originally investigated as a treatment for growth hormone deficiency before research interest expanded into other applications.
Yes. WADA prohibits CJC-1295 (with or without DAC) for athletes subject to drug testing under category S2 (Peptide Hormones, Growth Factors, Related Substances). The 6-8 day half-life and prolonged IGF-1 elevation make it particularly relevant to anti-doping concerns.
DAC:GRF, CJC-1295 with Drug Affinity Complex, and CJC-1295 DAC acetate (the salt form most commonly sold). Without DAC, the compound is called CJC-1295 or Modified GRF 1-29. The CAS number for CJC-1295 (no DAC) is 863288-34-0; the DAC version has its own variants.
GHRH receptor pharmacology and growth hormone secretion dynamics lead by volume. There's also active work in body composition research, IGF-1 axis studies, and aging-related GH decline models. The long half-life makes it particularly useful for chronic-exposure research designs that would be impractical with shorter-acting GHRH analogs.
The albumin-binding DAC tag is unique in this category — no other commonly available GHRH analog uses the same chemistry. That single modification turns a minutes-half-life peptide into a days-half-life peptide, which fundamentally changes what kind of research designs are practical. Sustained-exposure studies that would require 50+ injections with native GHRH can be done with one weekly dose using DAC.
